3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
3
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
Conditions
Tourette Syndrome
1
Stress Disorders, Post-Traumatic
1
Sleep Initiation and Maintenance Disorders
1
Severe Acute Respiratory Syndrome
1
Seizures
1
Parkinson Disease
1
Opioid-Related Disorders
1
Neoplasms
1
Multiple Sclerosis
1
Inflammatory Bowel Diseases
1
Hepatitis C
1
Glaucoma
1
Fibromyalgia
1
Epilepsy
1
Depression
1
Crohn Disease
1
Coronavirus Infections
1
Colitis, Ulcerative
1
Chronic Traumatic Encephalopathy
1
Chronic Pain
1
COVID-19
1
Brain Injuries, Traumatic
1
Bipolar Disorder
1
Autistic Disorder
1
Anxiety Disorders
1
Anemia, Sickle Cell
1
Amyotrophic Lateral Sclerosis
1
Acquired Immunodeficiency Syndrome
1
Interventions
Radiotherapy
299
Cisplatin
263
Cyclophosphamide
229
Doxorubicin
176
Paclitaxel
166
Vincristine
160
Carboplatin
149
Filgrastim
139
Etoposide
139
Gemcitabine
118
Fluorouracil
113
Docetaxel
112
Methotrexate
106
Dexamethasone
106
Cytarabine
106
Prednisone
91
Leucovorin
90
Granulocyte Colony-Stimulating Factor
74
Specimen Handling
65
Magnetic Resonance Spectroscopy
61
Capecitabine
59
Irinotecan
58
Radiation
54
Ifosfamide
51
Oxaliplatin
48
Daunorubicin
48
Temozolomide
47
Radiotherapy, Conformal
47
Platinum
47
Peripheral Blood Stem Cell Transplantation
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Interventional
×
Medical Marijuana
×
Clear all
NCT03944447
2022-06-02
OMNI-Can
OMNI Medical Services, LLC
Phase 2
Unknown
200,000 enrolled